WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561004
CAS#: 2002381-31-7 (HCl)
Description: APS-2-79 HCl is a modulator of KSR-dependent MAPK signaling, antagonizing RAF heterodimerization as well as the conformational changes required for phosphorylation and activation of KSR-bound MEK (mitogen-activated protein kinase).
Hodoodo Cat#: H561004
Name: APS-2-79 HCl
CAS#: 2002381-31-7 (HCl)
Chemical Formula: C23H22ClN3O3
Exact Mass: 0.00
Molecular Weight: 423.897
Elemental Analysis: C, 65.17; H, 5.23; Cl, 8.36; N, 9.91; O, 11.32
Related CAS #: 2002381-25-9 (free base) 2002381-31-7 (HCl)
Synonym: APS-2-79 HCl; APS2-79 HCl; APS 2-79 HCl; APS-279 HCl; APS279 HCl; APS 279 HCl;
IUPAC/Chemical Name: 6,7-Dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine Hydrochloride
InChi Key: LIXKSHWZJNNZHG-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H21N3O3.ClH/c1-15-11-17(29-16-7-5-4-6-8-16)9-10-19(15)26-23-18-12-21(27-2)22(28-3)13-20(18)24-14-25-23;/h4-14H,1-3H3,(H,24,25,26);1H
SMILES Code: CC1=CC(OC2=CC=CC=C2)=CC=C1NC3=C4C=C(OC)C(OC)=CC4=NC=N3.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
Soluble in DMSO | 0.0 | 100.00 |
The following data is based on the product molecular weight 423.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Neilsen BK, Frodyma DE, Lewis RE, Fisher KW. KSR as a therapeutic target for Ras-dependent cancers. Expert Opin Ther Targets. 2017 May;21(5):499-509. doi: 10.1080/14728222.2017.1311325. Epub 2017 Apr 7. Review. PubMed PMID: 28333549; PubMed Central PMCID: PMC5490495.
2: KSR Mutations Guide Development of RAS Pathway Antagonists. Cancer Discov. 2016 Oct;6(10):1079. Epub 2016 Sep 2. PubMed PMID: 27591198.